Addresses
Background Cotinine is the major metabolite of nicotine. It is also a specific biomarker for nicotine exposure in cigarette smokers. The measurement of urine cotinine concentration will enable: (1) the assessment of the smoking status of lung transplant patients and (2) tobacco abstinence to be studied in patients during treatment under smoking cessation programmes.
Methods
We have developed and validated a method for the measurement of urinary cotinine using reversed phase high-performance liquid chromatography (HPLC) coupled to tandem mass spectrometry (LC-MS/MS). This technique utilizes online ion exchange coupled with an analytical column to eliminate ion suppression effects. The chromatography was performed using a Waterst 2795 Alliance HT LC system.
Results
Cotinine and d3-cotinine had a retention time of 2.5 min and the cycle time from injection to injection was 4 min. The transition identified for cotinine was m/z 177.1479.6 and for d3-cotinine m/z 180.2479.6. This method was linear up to 1000 mg/L. Mean recovery of the assay was 112% with a range of 107-117% (n ¼ 9). The limit of quantitation for this assay was 2.5 mg/L and the limit of detection was 0.156 mg/L. The intra-and inter-assay imprecision was o12% and o10% respectively over a concentration range of 22-660 mg/L.
Introduction
Several biological markers have been proposed to assess the signi¢cance of direct and/or passive exposure to tobacco smoke. 1, 2 These include the measurement of carboxyhaemoglobin in blood, carbon monoxide in expired air, thiocyanate and nicotine in saliva, plasma or urine, and cotinine (which can be determined in urine, plasma, saliva, hair 2 and semen 3 ). However, some of these biomarkers may be in£uenced by other environmental sources other than tobacco smoke. For example, thiocyanate is a¡ected by diet, and carbon monoxide and carboxyhaemoglobin are a¡ected by road tra⁄c and domestic emissions.
The presence of nicotine and cotinine is attributable to tobacco smoke exposure, as cotinine is solely produced by nicotine metabolism, eliminating any environmental contamination. 2 The half-life of cotinine and nicotine are approximately 19 and 2 h respectively. 2 Consequently, cotinine, because of its longer half-life, is currently the marker of choice for demonstrating cigarette smoke exposure.
Cotinine is generally measured in urine as urine is easy to obtain, particularly when undertaking epidemiological studies. Cotinine measurements have facilitated many studies; notably those relating to nicotine replacement and smoking cessation. Extensive research on smoking cessation and urinary cotinine measurement has been undertaken at several centres, and as a result it has been used as a quantitative method to monitor smoking habits. 4--6 Various methods have been employed to measure cotinine including the colorimetric direct barbituric acid assay, used to measure urinary cotinine. Although this is a simple and cheap method, it also quanti¢es all those metabolites with an intact pyridine ring. This means that it may be relatively non-speci¢c. 2, 7 When using this method, cotinine concentrations in urine are higher than those obtained by more speci¢c methods (e.g. gas or liquid chromatography [LC] ). Furthermore, interferences due to the presence of drugs such as nicotinic acid, isoniazid and nicotinamide (which contain a pyridine ring) are major factors when interpreting cotinine concentrations. 2, 8 In order to increase assay speci¢city, immunological methods using monoclonal or polyclonal antibodies 2, 9 to speci¢cally bind to cotinine have been developed, which demonstrate minimal cross-reactivity with nicotine and other metabolites. 2, 9 However, it has been shown that trans-3-hydroxycotinine, which is known to be excreted in three-fold higher amounts than cotinine in smokers' urine, cross-reacts by approximately 30% with polyclonal rabbit anticotinine antiserum. This antibody is commonly used in methods to determine cotinine concentrations by enzyme-linked immunosorbent assay (ELISA), 2,10 leading to an overestimation of cotinine concentrations.
The most speci¢c methods of cotinine measurement are high-performance liquid chromatography (HPLC) and gas chromatography. These methods neither quantify interfering agents, which contain the pyridine ring, nor are they subject to cross-reactivity with trans-3hydroxycotinine. The identities of the peaks are veri¢able by mass spectrometry. 2,11--18 In our laboratory, we measure urine cotinine for two reasons; ¢rstly, to assess the smoking status of patients who are candidates for lung transplantation, and secondly, to assess the smoking status of patients who attend the hospital chest clinic.
The previous method of measurement of urine cotinine at our centre was the Microgenics CEDIA DRI s (Microgenics, Guildford, UK) cotinine enzyme immunoassay. This assay was abandoned due to the expense and poor performance of the assay. In this paper, we describe a method we have developed and validated in order to measure cotinine in urine using LC tandem mass spectrometry (LC-MS/MS).
Materials and methods

Patients' samples
Samples were collected for routine analysis of cotinine following local ethical approval.
Sample preparation
Preparation of standards
A 20,500 mg/L stock solution of d3-deuterated cotinine in 1mL of methanol (Sigma s -Aldrich Co Ltd, Poole, Dorset, UK) was prepared and stored at À201C. The working internal standard (IS) solution (100 mg/L) was prepared by diluting the stock solution in methanol. Standards were prepared by spiking cotinine (Sigma s -Aldrich) from a 5800 mg/L solution of cotinine in methanol that was kept at À201C into deionized water, to give concentrations ranging from 0 to 1000 mg/L. Aliquots were frozen and a new set was used for each batch.
Standards were prepared in deionized water as opposed to urine. Blank urine obtained from patients with cotinine concentrations o5 mg/L is di⁄cult to obtain due to passive smoking exposure, which most of the patients would experience. Since this assay is used routinely, it would be laborious to measure urine cotinine in each patient's urine sample and then prepare standards for every assay. 18 
Internal quality control material
Microgenics low and high cotinine quality control (QC) material, with cotinine concentrations of 222 and 660 mg/L, respectively (Microgenics) were used. As there was no commercial QC available below the cut-o¡ of 50 mg/L, the cotinine concentration of a patient's urine sample, analysed by LC-MS/MS, was utilized as QC for the validation of the assay. The cotinine concentration of this urine sample after 15 measurements had a mean value of 22 mg/L.
Sample preparation for analysis
Sample preparation comprised adding 10 mL of patient's urine, standard or internal QC material, to10 mL of IS in a 96-deep well plate. Acetonitrile (100 mL) was then added to each well, the plate was thermo-sealed and vortex-mixed for 60 s, then centrifuged for 5 min at 8000 g. The plate was transferred to the auto-sampler for analysis and 12 mL of sample was injected into the LC system.
Analysis
High-performance liquid chromatography
The chromatography was performed using a Waterst 2795 Alliance HT LC system (Waters Ltd, Elstree, Herts, UK). The analytical columns used were a Security-Guard strong cation exchange (SCX) column The mobile phases used were as follows: A (deionized water containing 2 mmol/L ammonium acetate with 0.1% (v/v) formic acid), B (methanol containing 2 mmol/L ammonium acetate with 0.1% (v/v) formic acid) and C (deionized water containing 100 mmol/L ammonium acetate with 0.1% (v/v) formic acid). Table 1 shows the gradients and £ow rates used. From 0 to 0.1min, cotinine was captured on to the SecurityGuard SCX column, which is used as an online solid phase extraction cartridge. From 0 to 0.8 min the mobile phase was pumped to waste using solvent delay. From 0.1 to 0.8 min cotinine was eluted o¡ the Securi-tyGuard SCX column, using a salt gradient (mobile phase C,90%) on to the Synergi Hydro-RP 80A analytical column. During the time period of 1.9--2.0 min cotinine was eluted from the Synergi Hydro-RP 80A column (mobile phase B, 80%). From 2 to 4 min the column was regenerated to starting conditions ready for the next sample awaiting analysis.
Mass spectrometry
A Micromass Quattro Microt tandem mass spectrometer (Waters Ltd, Elstree, Herts, UK) with a Z spray ion source was coupled to the HPLC system. Masslynx NT 3.5 software (provided with the mass spectrometer) was used for system control and the MassLynx Quan-Lynx program enabled data processing. To produce a standard curve the software used integration of the area under the chromatogram, 1/x weighting and linear least squares regression. The mass spectrometer was operated in electrospray positive mode; the capillary was kept at 1.00 kV and the source temperature maintained at 1401C. The gas £ow was 630 L/h and the desolvation temperature was kept at 3501C. The tuning of the mass spectrometer was carried out with 1000 mg/L solutions of cotinine and d3-cotinine in methanol. The cone energies were 30 V with collision energies of 24 eV for cotinine and 26 eV for d3-cotinine. The transitions were monitored in a multiple reaction monitoring (MRM) mode with a dwell time of 0.50 s. Inter-channel delay and the inter-scan delay were 0.02 and 0.03 s respectively.
Validation
Published criteria were used to perform the validation of the method. 19 In addition to determining the matrix induced ion suppression e¡ects, the accuracy, imprecision, recovery, linearity, speci¢city and stability of the method were each evaluated.
Ion suppression
Ion suppression is a matrix-associated phenomenon caused by compounds that co-elute with the compound of interest and compete for ionization in the mass spectrometer source. To investigate this phenomenon, a 200 mg/L solution of cotinine in methanol was infused directly into the mass spectrometer via the 'tee' piece, which enables a constant infusion of cotinine into the mobile phase stream while a sample injection is made. This allowed a constant signal in the speci¢c MRM channel for cotinine. When an extracted nonsmoker's urine sample was injected into the system via the LC, ion suppression was seen as a reduction (410%) in the speci¢c signal for cotinine. This study was performed with the SecurityGuard SCX column and the Synergi Hydro-RP 80A column separately, and then in series to assess the ion suppression e¡ect. The gradient conditions for the LC system were constant throughout the ion suppression study.
Accuracy and imprecision
Three concentrations of cotinine QC material were used to determine the intra-assay imprecision. The QC samples were extracted and were analysed 15 times in the same analytical run. 19 The coe⁄cient of variation (CV) of the replicates was required to be less than 15% to be deemed acceptable. Bias was assessed by calculating the percentage deviation from the di¡erence between the mean observed and nominal concentrations of the QC material. It was required to be less than 15% of the theoretical concentration. 19 Inter-assay imprecision was carried out by analysing the QC samples over a three-week period in 15 separate batches.
There is currently no external quality assurance (EQA) scheme in the UK for the measurement of cotinine in urine. As a consequence, we were unable to assess accuracy by studies on EQA material. 
Sensitivity
The lower limit of detection (LLoD) is de¢ned as the concentration of an analyte that gives a 3:1 signal to noise ratio. To determine the LLoD the following concentrations of cotinine were prepared in aqueous solution: 0.039, 0.078, 0.156 and 0.313 mg/L. The responses of these samples were assessed in order to determine which concentration of cotinine gave a 3:1 signal to noise ratio. The lower limit of quantitation (LLoQ) was determined by analysing the following concentrations of cotinine in aqueous solution: 0.313, 0.625, 1.25, 2.5 and 5 mg/L. Ten duplicates of each concentration were measured in the same batch. The lowest concentration of cotinine measurable with a CV of o20% and bias o20% was taken as the LLoQ. 19 
Linearity
To determine the linearity a standard curve was constructed with concentrations ranging from 0 to 1000 mg/L. The response was considered to be linear if the correlation coe⁄cient value was greater than 0.99, this was calculated using linear least squares regression.
Recovery
The recovery of cotinine need not be 100%, but the extent of recovery of cotinine and the IS should be consistent, precise and reproducible. 19 Three patients'samples were spiked with cotinine to give additional concentrations of 100, 450 and 900 mg/L. The recovery was determined by comparing the concentrations of cotinine both before and after the spiking.
Stability
In order to determine stability at di¡erent storage conditions, 12 patients' urine samples were stored at room temperature, 41C and À201C. To be considered stable the values of the samples measured needed to remain within 10% of the initial concentration. 19 To assess the stability of extracted cotinine QC samples over a 24 h period, the calculated response at t ¼ 24 was compared with the calculated response at t ¼ 0. The extract was considered stable if the calculated response values were within 10% of the initial values. 19 To determine the stability of an extracted urine sample upon repeated injection, 12 mL of sample was injected repeatedly every 12 min for 17 h and the cotinine/d3-cotinine peak area ratios were examined for any decrease that would indicate loss of stability. pH studies were carried out to assess stability of cotinine at pH values o2 and 49 over a four-day period at 41C and À201C.
Method comparison studies
Sixty-¢ve patients' samples were analysed by LC-MS/ MS and compared with results obtained when they were analysed on the ROCHE P-module (Roche Diagnostics, UK) using the Microgenics CEDIA DRI s cotinine assay.
Determination of reference interval
To distinguish those samples that were positive for cotinine from those that were negative, a cut-o¡ concentration was determined by measuring cotinine in urine collected from 50 non-smoker volunteers. All volunteers claimed that they did not use tobacco products. These results were compared to those obtained following the analysis of urine from 65 patients'samples.
Statistical analysis
All statistical analyses were performed using Analyse-It software (Analyse-It Software Ltd, Leeds, UK).
Results
Mass spectrometry
The transition identi¢ed for cotinine was m/z 177.1479.6. The ESI operating at 1.0 kV did give some fragmentation of the parent ion as the daughter ion at m/z 79.6 was already present. This was caused by the source conditions. However, this did not a¡ect the quantitation or sensitivity of the method. Transition for d3-cotinine was m/z 180.2479.6. After preparation the samples gave a colourless and clear supernatant, producing chromatograms, which were clear of interferants. Both cotinine and d3-cotinine had a retention time of 2.5 min and the cycle time from injection to injection was 4 min (Figure 1 ).
Validation
Ion suppression
Ion suppression studies performed using the Synergi Hydro-RP 80A column demonstrated the main region of ion suppression occurring at approximately 0.35 min, and cotinine eluting from the column in the area of ion suppression at 0.37 min, with an absolute signal suppression of $100%. Ion suppression using the SecurityGuard SCX column showed regions of ion suppression occurring at 0.22 and $1min and cotinine eluting from the column in the region of ion suppression at 1.00 min, with an absolute signal suppression of $95%. However, when using the two columns in series, the main regions of ion suppression occurred at $0.35 and 1.3 min. Moreover, the absolute signal suppression was reduced to 0%, giving no signi¢cant ion suppression in the region of 2.5 min where cotinine elutes (Figure 2 ). Linearity A linear standard curve was observed over the range (0--1000 mg/L). The standard curve was reproducible between batches and showed good correlation with 
Sensitivity and imprecision
The LLoD was 0.156 mg/L and the LLoQ was 2.5 mg/L (Figure 3) . The mean recovery of the assay was 112% (range 107--117%). Table 2 shows that the inter-and intra-assay imprecision were both acceptable at o13%. Inter-and intra-assay bias were both acceptable at o12% and o6% respectively.
Stability studies
The extract was stable during repeated injections over a17 h period and the CV for peak area ratio (analyte/IS) was 3.8%, indicating that there was no systematic loss of stability. The mean and standard deviation of the peak area ratios were 1.03 and 0.04 respectively. The QC samples were deemed to be stable for 24 h as the decrease in response was 4% at all concentrations. Samples stored at room temperature over a ¢ve-day period showed a decrease in cotinine concentration greater than 10%, as did samples kept at 41C. However, samples frozen at À201C showed improved stability over the ¢ve-day period. The mean decrease in cotinine concentration was o10%. The results for the alteration of urine pH at values o2 and 49 and subsequent storage at 41C and À201C over the four-day period showed no improvement in urine cotinine stability.
The results indicate that urine cotinine should be analysed on the day of collection. However, if this is not possible, we have shown that samples may be stored at À201C for up to ¢ve days, i.e. the time period of this study. There has been limited research into the stability of urine cotinine. Moyer et al. 17 investigated urine cotinine stability in pools stored at ambient temperatures, 41C and À201C. Their ¢ndings demonstrated a variability and inconsistency in the observed stability of cotinine, not just between samples stored at di¡erent temperature, but between samples stored at the same temperature.
Method comparison studies
The results of the method comparison are shown in Figure 4 . The Microgenics CEDIA DRI s cotinine assay gave higher values than the LC-MS/MS assay. The regression line was LC-MS/MS ¼ 0.748 Â Microgenics CEDIA DRI s þ 37.34 and the correlation coe⁄cient value was 0.94. When the LC-MS/MS calibrators were analysed on the Microgenics CEDIA DRI s assay it was noted that the assay was unable to measure the 5 mg/L standard. However there was no signi¢cant di¡erence between the values obtained by both methods (P ¼ 0.98, paired t-test). The Microgenics assay calibrators were analysed on the LC-MS/MS along with freshly prepared cotinine standards, and no signi¢cant di¡erence was observed between the values obtained (P ¼ 0.44, paired t-test).
Reference interval
The reference interval determined from the measurement of 50 non-smokers' samples identi¢ed cotinine concentrations that varied from undetectable to having a concentration of less than 5 mg/L. From the 65 patients' samples that had cotinine concentrations determined, urine samples from smokers were identi¢ed as having cotinine values that were all greater than 50 mg/L.
Discussion
In this study, we have developed a robust and simple method to measure cotinine in urine. We have not measured other metabolites such as trans-3-hydroxycotinine, because, although it has theoretically fourfold more sensitivity over cotinine measurement, it does not lead to greater clinical usefulness. Furthermore, 0.00 0.50 1.00 1.50 2.00 2.50 3.00 3. Figure 3 This chromatogram shows a cotinine peak at a concentration of 2.5 mg/L, which was determined to be the LLoQ for the cotinine assay on the LC-MS/MS, with a CV and bias of o20% measuring further metabolites makes the assay more complicated, for example, mixed calibrators have to be made regularly and multiple ISs also need to be used. Preparing calibrators and QC material can be onerous if commercially available material is unavailable. By measuring cotinine alone we were able to use commercially available material. Using our method, sample transfer into autosampler vials is not necessary as all sample preparation is performed in a 96-deep well plate, which can ¢t directly onto the autosampler of the LC system. Twenty-four hour urine collections are not required as the analysis is carried out on random urine samples, 11 with a minimal sample volume requirement (10 mL). We have reduced the sample preparation times signi¢cantly and simpli¢ed the sample extraction procedure compared with those methods, which require solid phase extraction 11, 12, 16, 18 and those where overnight sample preparation is required. 18 This method was developed to be utilized in a routine hospital laboratory, therefore we kept the sample preparation to a minimum.
We found that the combination of ion exchange and analytical column minimized ion suppression and reduced interference. The method described has an improved recovery of urine cotinine, compared to a number of methods which demonstrated a relatively poor recovery. This can be attributed to reduced solid phase extraction e⁄ciency for urinary cotinine. 12, 17 The LC-MS/MS has potentially greater speci¢city for cotinine compared with immunoassay techniques. The speci¢city is enhanced due to the chromatographic separation of the analyte of interest from interfering substances and the selectivity of the mass-to-charge ratio of cotinine by the tandem mass spectrometer. It is not surprising that the Microgenics CEDIA DRI s cotinine assay gave higher values for patients' urine cotinine samples, as the assay may be subject to crossreactivity from cotinine metabolites present in patients' urine.
Analysis of each sample is completed within 4 min on the LC-MS/MS, and cotinine and d3-cotinine both have a retention time of only 2.5 min, which is fast when compared with other methods. 12, 16, 18 The measurement of cotinine is not an urgent investigation. In our centre, we run the cotinine assay weekly to assess the smoking status of patients who are being considered for cardiothoracic transplantation while attending the assessment clinics. This weekly provision of the assay is considered satisfactory by the users of the service and meets their needs and requirements.
The Microgenics CEDIA DRI s cotinine assay is available to buy in reagent pack sizes of either 100 or 500 mL, which are su⁄cient for about 670 and 3350 tests respectively. The frequency of analysis in our Department would therefore dictate large kit wastage in our case. The LC-MS/MS has a capital cost of approximately »150,000; however, when implemented it is e⁄cient to run. Service contract costs for the use of the LC-MS/MS are »12,000. In our centre we run several assays including female testosterone, androstenedione, urine-free cortisol, cyclosporine, tacrolimus and many more. The LC-MS/MS was not purchased solely to measure urine cotinine, and by running other assays the cost of each individual assay can be reduced. We use low-priced ion exchange guard cartridges and the analytical column remains functional after two years of use. While reagent costs for LC-MS/MS are low, the labour costs may be slightly higher compared to the Microgenics CEDIA DRI s cotinine assay on an automated analyser. We believe this method has arguably improved upon current LC-MS/MS methods and is well suited for routine use in the clinical biochemistry laboratory.
